Does the media refer more to OMER or SUPN?

In the previous week, Supernus Pharmaceuticals had 4 more articles in the media than Omeros. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 4 mentions for Omeros. Supernus Pharmaceuticals' average media sentiment score of 1.21 beat Omeros' score of 0.41 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is OMER or NKTR more profitable?

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Nektar Therapeutics -284.18% -85.40% -39.99%

Does the media refer more to OMER or NKTR?

In the previous week, Nektar Therapeutics had 1 more articles in the media than Omeros. MarketBeat recorded 5 mentions for Nektar Therapeutics and 4 mentions for Omeros. Nektar Therapeutics' average media sentiment score of 1.19 beat Omeros' score of 0.41 indicating that Nektar Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nektar Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, OMER or PRGO?

Omeros has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros $9.89M 86.62 -$3.35M $0.70 16.91 Perrigo $4.18B 0.33 -$1.43B -$13.10 N/A

Is OMER or PRGO more profitable?

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Perrigo -43.50% 9.96% 3.90%

Does the media refer more to OMER or PRGO?

In the previous week, Perrigo had 8 more articles in the media than Omeros. MarketBeat recorded 12 mentions for Perrigo and 4 mentions for Omeros. Perrigo's average media sentiment score of 1.17 beat Omeros' score of 0.41 indicating that Perrigo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Perrigo 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, OMER or PCRX?

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Omeros $9.89M 86.62 -$3.35M $0.70 16.91 Pacira BioSciences $726.41M 1.43 $7.03M $0.12 220.08

Is OMER or PCRX more profitable?

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Omeros N/A -102.16% 64.87% Pacira BioSciences 0.70% 10.24% 5.47%

Does the media favor OMER or PCRX?

In the previous week, Pacira BioSciences had 7 more articles in the media than Omeros. MarketBeat recorded 11 mentions for Pacira BioSciences and 4 mentions for Omeros. Pacira BioSciences' average media sentiment score of 0.67 beat Omeros' score of 0.41 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pacira BioSciences 5 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media favor OMER or ASMB?

In the previous week, Omeros had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 4 mentions for Omeros and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.56 beat Omeros' score of 0.41 indicating that Assembly Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Omeros 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Assembly Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Omeros (OMER) Competitors

$11.84 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$12.16 +0.32 (+2.70%)

As of 07/31/2026 07:36 PM Eastern

Compare

OMER vs. SUPN, NKTR, PRGO, PCRX, and ASMB

Should you buy Omeros stock or one of its competitors? MarketBeat compares Omeros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Omeros include Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Perrigo (PRGO), Pacira BioSciences (PCRX), and Assembly Biosciences (ASMB).

How does Omeros compare to Supernus Pharmaceuticals?

Omeros (NASDAQ:OMER) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Omeros has a beta of 2.55, suggesting that its stock price is 155% more volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Omeros has higher earnings, but lower revenue than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$9.89M	86.62	-$3.35M	$0.70	16.91
Supernus Pharmaceuticals	$718.95M	3.60	-$38.55M	-$0.51	N/A

In the previous week, Supernus Pharmaceuticals had 4 more articles in the media than Omeros. MarketBeat recorded 8 mentions for Supernus Pharmaceuticals and 4 mentions for Omeros. Supernus Pharmaceuticals' average media sentiment score of 1.21 beat Omeros' score of 0.41 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%

48.8% of Omeros shares are held by institutional investors. 10.5% of Omeros shares are held by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Omeros presently has a consensus target price of $38.00, suggesting a potential upside of 220.95%. Supernus Pharmaceuticals has a consensus target price of $62.83, suggesting a potential upside of 40.79%. Given Omeros' stronger consensus rating and higher possible upside, analysts plainly believe Omeros is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Omeros beats Supernus Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Omeros compare to Nektar Therapeutics?

Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Omeros presently has a consensus target price of $38.00, suggesting a potential upside of 220.95%. Nektar Therapeutics has a consensus target price of $150.00, suggesting a potential upside of 112.25%. Given Omeros' higher possible upside, analysts plainly believe Omeros is more favorable than Nektar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Nektar Therapeutics had 1 more articles in the media than Omeros. MarketBeat recorded 5 mentions for Nektar Therapeutics and 4 mentions for Omeros. Nektar Therapeutics' average media sentiment score of 1.19 beat Omeros' score of 0.41 indicating that Nektar Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nektar Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has higher earnings, but lower revenue than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$9.89M	86.62	-$3.35M	$0.70	16.91
Nektar Therapeutics	$55.23M	43.24	-$164.08M	-$8.42	N/A

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -284.18%. Nektar Therapeutics' return on equity of -85.40% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Nektar Therapeutics	-284.18%	-85.40%	-39.99%

48.8% of Omeros shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 2.5% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Omeros has a beta of 2.55, indicating that its stock price is 155% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Summary

Omeros beats Nektar Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Omeros compare to Perrigo?

Omeros (NASDAQ:OMER) and Perrigo (NYSE:PRGO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Omeros has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$9.89M	86.62	-$3.35M	$0.70	16.91
Perrigo	$4.18B	0.33	-$1.43B	-$13.10	N/A

In the previous week, Perrigo had 8 more articles in the media than Omeros. MarketBeat recorded 12 mentions for Perrigo and 4 mentions for Omeros. Perrigo's average media sentiment score of 1.17 beat Omeros' score of 0.41 indicating that Perrigo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Perrigo	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market. Comparatively, Perrigo has a beta of 0.51, suggesting that its share price is 49% less volatile than the broader market.

Omeros has a net margin of 0.00% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Perrigo	-43.50%	9.96%	3.90%

48.8% of Omeros shares are owned by institutional investors. Comparatively, 95.9% of Perrigo shares are owned by institutional investors. 10.5% of Omeros shares are owned by company insiders. Comparatively, 0.4% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Omeros presently has a consensus price target of $38.00, indicating a potential upside of 220.95%. Perrigo has a consensus price target of $19.33, indicating a potential upside of 91.70%. Given Omeros' stronger consensus rating and higher possible upside, equities research analysts plainly believe Omeros is more favorable than Perrigo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Omeros beats Perrigo on 12 of the 17 factors compared between the two stocks.

How does Omeros compare to Pacira BioSciences?

Omeros (NASDAQ:OMER) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

Omeros has a beta of 2.55, suggesting that its share price is 155% more volatile than the broader market. Comparatively, Pacira BioSciences has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Pacira BioSciences has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$9.89M	86.62	-$3.35M	$0.70	16.91
Pacira BioSciences	$726.41M	1.43	$7.03M	$0.12	220.08

48.8% of Omeros shares are owned by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are owned by institutional investors. 10.5% of Omeros shares are owned by insiders. Comparatively, 6.4% of Pacira BioSciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Pacira BioSciences had 7 more articles in the media than Omeros. MarketBeat recorded 11 mentions for Pacira BioSciences and 4 mentions for Omeros. Pacira BioSciences' average media sentiment score of 0.67 beat Omeros' score of 0.41 indicating that Pacira BioSciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pacira BioSciences	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Omeros presently has a consensus target price of $38.00, indicating a potential upside of 220.95%. Pacira BioSciences has a consensus target price of $29.40, indicating a potential upside of 11.32%. Given Omeros' stronger consensus rating and higher probable upside, research analysts plainly believe Omeros is more favorable than Pacira BioSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Pacira BioSciences	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Pacira BioSciences has a net margin of 0.70% compared to Omeros' net margin of 0.00%. Pacira BioSciences' return on equity of 10.24% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Pacira BioSciences	0.70%	10.24%	5.47%

Summary

Pacira BioSciences beats Omeros on 9 of the 17 factors compared between the two stocks.

How does Omeros compare to Assembly Biosciences?

Omeros (NASDAQ:OMER) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

Omeros has a net margin of 0.00% compared to Assembly Biosciences' net margin of -8.98%. Assembly Biosciences' return on equity of -4.21% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omeros	N/A	-102.16%	64.87%
Assembly Biosciences	-8.98%	-4.21%	-3.14%

Omeros has a beta of 2.55, meaning that its share price is 155% more volatile than the broader market. Comparatively, Assembly Biosciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Omeros currently has a consensus price target of $38.00, suggesting a potential upside of 220.95%. Assembly Biosciences has a consensus price target of $44.00, suggesting a potential upside of 75.23%. Given Omeros' higher probable upside, analysts clearly believe Omeros is more favorable than Assembly Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omeros	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Omeros had 2 more articles in the media than Assembly Biosciences. MarketBeat recorded 4 mentions for Omeros and 2 mentions for Assembly Biosciences. Assembly Biosciences' average media sentiment score of 0.56 beat Omeros' score of 0.41 indicating that Assembly Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omeros	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Assembly Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

48.8% of Omeros shares are held by institutional investors. Comparatively, 19.9% of Assembly Biosciences shares are held by institutional investors. 10.5% of Omeros shares are held by company insiders. Comparatively, 3.5% of Assembly Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Omeros has higher earnings, but lower revenue than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omeros	$9.89M	86.62	-$3.35M	$0.70	16.91
Assembly Biosciences	$72.30M	5.52	-$6.12M	-$0.11	N/A

Summary

Omeros beats Assembly Biosciences on 12 of the 17 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMER vs. The Competition

Export

Metric	Omeros	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$856.92M	$3.54B	$6.86B	$12.42B
Dividend Yield	N/A	3.78%	2.59%	10.03%
P/E Ratio	16.91	7.38	282.30	24.66
Price / Sales	86.62	1,201.52	564.98	76.51
Price / Cash	6.33	44.80	28.60	46.71
Price / Book	-6.92	16.78	10.92	6.07
Net Income	-$3.35M	-$12.56M	$3.49B	$347.99M
7 Day Performance	4.41%	-1.79%	-0.64%	-0.44%
1 Month Performance	27.59%	-8.41%	-5.24%	-4.81%
1 Year Performance	227.98%	48.37%	61.98%	18.61%

Omeros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMER Omeros	2.9882 of 5 stars	$11.84 flat	$38.00 +220.9%	+228.0%	$856.92M	$9.89M	16.91	210
SUPN Supernus Pharmaceuticals	3.8186 of 5 stars	$46.98 +1.7%	$62.83 +33.7%	+25.7%	$2.68B	$718.95M	N/A	580	Upcoming Earnings Short Interest Decrease
NKTR Nektar Therapeutics	2.942 of 5 stars	$71.35 +0.9%	$150.00 +110.2%	+207.8%	$2.39B	$55.23M	N/A	220	Positive News
PRGO Perrigo	4.4108 of 5 stars	$10.17 +0.8%	$19.33 +90.1%	-62.2%	$1.40B	$4.18B	N/A	8,100	Positive News Upcoming Earnings Dividend Announcement
PCRX Pacira BioSciences	2.0478 of 5 stars	$26.47 +2.3%	$29.40 +11.1%	+19.7%	$1.02B	$726.41M	220.60	720	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMER) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omeros (OMER) Competitors

OMER vs. SUPN, NKTR, PRGO, PCRX, and ASMB

How does Omeros compare to Supernus Pharmaceuticals?

Summary

How does Omeros compare to Nektar Therapeutics?

Summary

How does Omeros compare to Perrigo?

Summary

How does Omeros compare to Pacira BioSciences?

Summary

How does Omeros compare to Assembly Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omeros (OMER) Competitors

OMER vs. SUPN, NKTR, PRGO, PCRX, and ASMB

How does Omeros compare to Supernus Pharmaceuticals?

Which has more volatility and risk, OMER or SUPN?

Which has stronger earnings & valuation, OMER or SUPN?

Does the media refer more to OMER or SUPN?

Is OMER or SUPN more profitable?

Do institutionals and insiders have more ownership in OMER or SUPN?

Do analysts recommend OMER or SUPN?

Summary

How does Omeros compare to Nektar Therapeutics?

Do analysts rate OMER or NKTR?

Does the media refer more to OMER or NKTR?

Which has higher earnings & valuation, OMER or NKTR?

Is OMER or NKTR more profitable?

Do insiders and institutionals have more ownership in OMER or NKTR?

Which has more volatility & risk, OMER or NKTR?

Summary

How does Omeros compare to Perrigo?

Which has higher earnings and valuation, OMER or PRGO?

Does the media refer more to OMER or PRGO?

Which has more volatility & risk, OMER or PRGO?

Is OMER or PRGO more profitable?

Do institutionals and insiders have more ownership in OMER or PRGO?

Do analysts rate OMER or PRGO?

Summary

How does Omeros compare to Pacira BioSciences?

Which has more risk and volatility, OMER or PCRX?

Which has better valuation & earnings, OMER or PCRX?

Do institutionals and insiders believe in OMER or PCRX?

Does the media favor OMER or PCRX?

Do analysts prefer OMER or PCRX?

Is OMER or PCRX more profitable?

Summary

How does Omeros compare to Assembly Biosciences?

Is OMER or ASMB more profitable?

Which has more risk & volatility, OMER or ASMB?

Do analysts recommend OMER or ASMB?

Does the media favor OMER or ASMB?

Do institutionals and insiders hold more shares of OMER or ASMB?

Which has preferable valuation and earnings, OMER or ASMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMER vs. The Competition

Omeros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools